These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37002895)

  • 1. Synthesis and Anti-Mycobacterium tuberculosis Activity of Imidazo[2,1-b][1,3]oxazine Derivatives against Multidrug-Resistant Strains.
    Fernandes GFS; Manieri KF; Bonjorno AF; Campos DL; Ribeiro CM; Demarqui FM; Ruiz DAG; Nascimento-Junior NM; Denny WA; Thompson AM; Pavan FR; Dos Santos JL
    ChemMedChem; 2023 Jun; 18(12):e202300015. PubMed ID: 37002895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3D QSAR, Docking, Molecular Dynamics Simulations and MM-GBSA studies of Extended Side Chain of the Antitubercular Drug (6S) 2-Nitro-6- {[4-(trifluoromethoxy) benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine.
    Chaudhari HK; Pahelkar A
    Infect Disord Drug Targets; 2019; 19(2):145-166. PubMed ID: 30324898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of benzo[c]phenanthridine derivatives with potent activity against multidrug-resistant
    Liang YC; Sun Z; Lu C; Lupien A; Xu Z; Berton S; Xu P; Behr MA; Yang W; Sun J
    Microbiol Spectr; 2024 Nov; 12(11):e0124624. PubMed ID: 39361873
    [No Abstract]   [Full Text] [Related]  

  • 4. Synthesis and anti-tubercular activity of 2-nitroimidazooxazines with modification at the C-7 position as PA-824 analogs.
    Kang YG; Park CY; Shin H; Singh R; Arora G; Yu CM; Lee IY
    Bioorg Med Chem Lett; 2015 Sep; 25(17):3650-3. PubMed ID: 26199118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel C-3-(N-alkyl-aryl)-aminomethyl rifamycin SV derivatives exhibit activity against rifampicin-resistant Mycobacterium tuberculosis RpoB
    Zloh M; Gupta M; Parish T; Brucoli F
    Eur J Med Chem; 2021 Dec; 225():113734. PubMed ID: 34418786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, Biological Evaluation and Molecular Docking Studies of New Pyrazolines as an Antitubercular and Cytotoxic Agents.
    Lokesh BVS; Prasad YR; Shaik AB
    Infect Disord Drug Targets; 2019; 19(3):310-321. PubMed ID: 30556506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis.
    Upton AM; Cho S; Yang TJ; Kim Y; Wang Y; Lu Y; Wang B; Xu J; Mdluli K; Ma Z; Franzblau SG
    Antimicrob Agents Chemother; 2015 Jan; 59(1):136-44. PubMed ID: 25331696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((s)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-amino PA-824).
    Cherian J; Choi I; Nayyar A; Manjunatha UH; Mukherjee T; Lee YS; Boshoff HI; Singh R; Ha YH; Goodwin M; Lakshminarayana SB; Niyomrattanakit P; Jiricek J; Ravindran S; Dick T; Keller TH; Dartois V; Barry CE
    J Med Chem; 2011 Aug; 54(16):5639-59. PubMed ID: 21755942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naphthofuroquinone derivatives show strong antimycobacterial activities against drug-resistant Mycobacteria.
    Jang WS; Choi YS; Kim S; Jyoti MA; Seo H; Han J; Kim YS; Lyu J; Nam KW; Lee BE; Lee KI; Song HY
    J Chemother; 2017 Dec; 29(6):338-343. PubMed ID: 28281912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico Design and Synthesis of Tetrahydropyrimidinones and Tetrahydropyrimidinethiones as Potential Thymidylate Kinase Inhibitors Exerting Anti-TB Activity Against
    Venugopala KN; Tratrat C; Pillay M; Chandrashekharappa S; Al-Attraqchi OHA; Aldhubiab BE; Attimarad M; Alwassil OI; Nair AB; Sreeharsha N; Venugopala R; Morsy MA; Haroun M; Kumalo HM; Odhav B; Mlisana K
    Drug Des Devel Ther; 2020; 14():1027-1039. PubMed ID: 32214795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, antitubercular profile and molecular docking studies of quinazolinone-based pyridine derivatives against drug-resistant tuberculosis.
    Raghu MS; Yogesh Kumar K; Shamala T; Alharti FA; Prashanth MK; Jeon BH
    J Biomol Struct Dyn; 2024 Apr; 42(7):3307-3317. PubMed ID: 37261798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacophore modeling of pretomanid (PA-824) derivatives for antitubercular potency against replicating and non-replicating
    Aher RB; Sarkar D
    J Biomol Struct Dyn; 2021 Feb; 39(3):889-900. PubMed ID: 31983295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hybrid Design of Isonicotinic Acid Hydrazide Derivatives: Machine Learning Studies, Synthesis and Biological Evaluation of their Antituberculosis Activity.
    Kovalishyn V; Hodyna D; Sinenko VO; Blagodatny V; Semenyuta I; Slivchuk SR; Brovarets V; Poda G; Metelytsia L
    Curr Drug Discov Technol; 2020; 17(3):365-375. PubMed ID: 30973110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Activities and Secretion of Cytokines Caused by Delamanid on Macrophages Infected by Multidrug-Resistant
    Lyu XL; Lin TT; Gao JT; Jia HY; Zhu CZ; Li ZH; Dong J; Sun Q; Shu W; Pan LP; Zhang ZD; Li Q
    Front Immunol; 2021; 12():796677. PubMed ID: 35003120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery, Synthesis, and Optimization of 1,2,4-Triazolyl Pyridines Targeting
    Berida T; McKee SR; Chatterjee S; Manning DL; Li W; Pandey P; Tripathi SK; Mreyoud Y; Smirnov A; Doerksen RJ; Jackson M; Ducho C; Stallings CL; Roy S
    ACS Infect Dis; 2023 Nov; 9(11):2282-2298. PubMed ID: 37788674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and biological evaluation of novel imidazo[1,2-a]pyridinecarboxamides as potent anti-tuberculosis agents.
    Onajole OK; Lun S; Yun YJ; Langue DY; Jaskula-Dybka M; Flores A; Frazier E; Scurry AC; Zavala A; Arreola KR; Pierzchalski B; Ayitou AJ; Bishai WR
    Chem Biol Drug Des; 2020 Dec; 96(6):1362-1371. PubMed ID: 32515129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Medicinal Chemistry of Chalcones as Anti-
    Rodríguez-Silva CN; Prokopczyk IM; Dos Santos JL
    Mini Rev Med Chem; 2022; 22(16):2068-2080. PubMed ID: 35156577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro bioevaluation and docking study of dihydrosphingosine and ethambutol analogues against sensitive and multi-drug resistant Mycobacterium tuberculosis.
    Linhares LA; Dos Santos Peixoto A; Correia de Sousa LA; Lucena Laet JP; da Silva Santos AC; Alves Pereira VR; Carneiro Neves MM; Ferreira LFGR; Hernandes MZ; de la Vega J; Pereira-Neves A; San Feliciano A; Olmo ED; Schindler HC; Montenegro LML
    Eur J Med Chem; 2023 Oct; 258():115579. PubMed ID: 37399709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naphthoquinones isolated from Diospyros anisandra exhibit potent activity against pan-resistant first-line drugs Mycobacterium tuberculosis strains.
    Uc-Cachón AH; Borges-Argáez R; Said-Fernández S; Vargas-Villarreal J; González-Salazar F; Méndez-González M; Cáceres-Farfán M; Molina-Salinas GM
    Pulm Pharmacol Ther; 2014 Feb; 27(1):114-20. PubMed ID: 23968826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-mycobacterial activity of plumericin and isoplumericin against MDR Mycobacterium tuberculosis.
    Kumar P; Singh A; Sharma U; Singh D; Dobhal MP; Singh S
    Pulm Pharmacol Ther; 2013 Jun; 26(3):332-5. PubMed ID: 23333815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.